Trial Profile
A phase II trial of Abraxane given weekly as a single agent in first-line treatment of metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2012
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Dec 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 01 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Nov 2010 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.